Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective humanized recombinant monoclonal antibody targeting the IL-13 molecule with high specificity. It demonstrates potent affinity for both the wild-type and variant forms of human IL-13, effectively inhibiting IL-13's interaction with its receptors, IL-13Rα1 and IL-13Rα2, as evidenced by IC50 values of 352 pM and 631 pM, respectively, determined via ELISA. Furthermore, Cendakimab binds with comparable affinities of 52 pM and 50 pM to the wild-type human IL-13 and its common R110Q polymorphic variant. This antibody holds therapeutic potential for treating IL-13-related allergic and inflammatory conditions, such as asthma and eosinophilic esophagitis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Cendakimab (RPC4046; ABT 308; CC-93538) is a selective humanized recombinant monoclonal antibody targeting the IL-13 molecule with high specificity. It demonstrates potent affinity for both the wild-type and variant forms of human IL-13, effectively inhibiting IL-13's interaction with its receptors, IL-13Rα1 and IL-13Rα2, as evidenced by IC50 values of 352 pM and 631 pM, respectively, determined via ELISA. Furthermore, Cendakimab binds with comparable affinities of 52 pM and 50 pM to the wild-type human IL-13 and its common R110Q polymorphic variant. This antibody holds therapeutic potential for treating IL-13-related allergic and inflammatory conditions, such as asthma and eosinophilic esophagitis. |
Molecular Weight | N/A |
CAS No. | 2151032-62-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cendakimab 2151032-62-9 inhibitor inhibit